Nanocarriers as Potential Targeted Drug Delivery for Cancer Therapy

Singhvi, Gautam; Rapalli, Vamshi Krishna; Nagpal, Shakti; Dubey, Sunil Kumar; Saha, Ranendra Narayan

doi:10.1007/978-3-030-29207-2_2

Cited by 26 publications

(20 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[42][43][44] A comparative description of the various nanocarriers with their pros and cons is provided in Table 2. 21,[45][46][47][48][49][50][51][52][53][54][55][56][57][58][59] Some examples of recent ndings with the above-mentioned nanocarriers for the treatment of ophthalmic diseases are compiled in Table 3. [60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79]…”

Section: Importance Of Nanomedicine In Ocular Drug Delivery Systemsmentioning

confidence: 99%

Nanocarriers for ocular drug delivery: current status and translational opportunity

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Importance Of Nanomedicine In Ocular Drug Delivery Systemsmentioning

confidence: 99%

Nanocarriers for ocular drug delivery: current status and translational opportunity

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another major challenge in the development of drug delivery systems is the drug targeting mechanism. Micro and nanocarriers can be able to achieve tissue or cell targeting through an active or passive mechanism (Singhvi et al 2020 ). In passive targeting, the drug can be delivered to the target passively based on the longevity of the pharmaceutical into the site of interest; while the active targeting is based on the attachment of a specific recognition element like ligand receptor, antigen–antibody to the surface of the carriers to deliver drugs to a specific location (Behera and Padhi 2020 ).…”

Section: Drug Encapsulation and In Vitro And In Vivo Releasementioning

confidence: 99%

Recent advances in the formulation of PLGA microparticles for controlled drug delivery

et al. 2020

View full text Add to dashboard Cite

Polymeric microparticles (MPs) are recognized as very popular carriers to increase the bioavailability and bio-distribution of both lipophilic and hydrophilic drugs. Among different kinds of polymers, poly-(lactic-co-glycolic acid) (PLGA) is one of the most accepted materials for this purpose, because of its biodegradability (due to the presence of ester linkages that are degraded by hydrolysis in aqueous environments) and safety (PLGA is a Food and Drug Administration (FDA)-approved compound). Moreover, its biodegradability depends on the number of glycolide units present in the structure, indeed, lower glycol content results in an increased degradation time and conversely a higher monomer unit number results in a decreased time. Due to this feature, it is possible to design and fabricate MPs with a programmable and time-controlled drug release. Many approaches and procedures can be used to prepare MPs. The chosen fabrication methodology influences size, stability, entrapment efficiency, and MPs release kinetics. For example, lipophilic drugs as chemotherapeutic agents (doxorubicin), anti-inflammatory non-steroidal (indomethacin), and nutraceuticals (curcumin) were successfully encapsulated in MPs prepared by single emulsion technique, while water-soluble compounds, such as aptamer, peptides and proteins, involved the use of double emulsion systems to provide a hydrophilic compartment and prevent molecular degradation. The purpose of this review is to provide an overview about the preparation and characterization of drug-loaded PLGA MPs obtained by single, double emulsion and microfluidic techniques, and their current applications in the pharmaceutical industry. Graphic abstract

show abstract

“…Amphiphilic lipids like glyceryl monoolein, phytantriol, and lecithin are widely used in the preparation of LCNPs. These lipids are biocompatible, biodegradable, and economical (71)(72)(73). The LCNP-based formulation poses several advantages like controlled drug release, improved stability of the drug, and entrapment of hydrophilic, hydrophobic, and amphiphilic drugs (74,75).…”

Section: Liquid Crystal Nanoparticles (Lcnps) For Topical Delivery Of Curcuminmentioning

confidence: 99%

Emerging Trends in Topical Delivery of Curcumin Through Lipid Nanocarriers: Effectiveness in Skin Disorders

et al. 2020

Self Cite

View full text Add to dashboard Cite

Curcumin is a unique molecule naturally obtained from rhizomes of Curcuma longa. Curcumin has been reported to act on diverse molecular targets like receptors, enzymes, and co-factors; regulate different cellular signaling pathways; and modulate gene expression. It suppresses expression of main inflammatory mediators like interleukins, tumor necrosis factor, and nuclear factor κB which are involved in the regulation of genes causing inflammation in most skin disorders. The topical delivery of curcumin seems to be more advantageous in providing a localized effect in skin diseases. However, its low aqueous solubility, poor skin permeation, and degradation hinder its application for commercial use despite its enormous potential. Lipid-based nanocarrier systems including liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, lyotropic liquid crystal nanoparticles, lipospheres, and lipid nanocapsules have found potential as carriers to overcome the issues associated with conventional topical dosage forms. Nano-size, lipophilic nature, viscoelastic properties, and occlusive effect of lipid nanocarriers provide high drug loading, hydration of skin, stability, enhanced permeation through the stratum corneum, and slow release of curcumin in the targeted skin layers. This review particularly focuses on the application of lipid nanocarriers for the topical delivery of curcumin in the treatment of various skin diseases. Furthermore, preclinical studies and patents have also indicated the emerging commercialization potential of curcumin-loaded lipid nanocarriers for effective drug delivery in skin disorders.

show abstract

Nanocarriers as Potential Targeted Drug Delivery for Cancer Therapy

Cited by 26 publications

References 130 publications

Nanocarriers for ocular drug delivery: current status and translational opportunity

Nanocarriers for ocular drug delivery: current status and translational opportunity

Recent advances in the formulation of PLGA microparticles for controlled drug delivery

Emerging Trends in Topical Delivery of Curcumin Through Lipid Nanocarriers: Effectiveness in Skin Disorders

Contact Info

Product

Resources

About